SBHMY Sino Biopharmaceutical Ltd. Forecast, Technical & Fundamental Analysis

SBHMY in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 16, 2025

SBHMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 24 cases where SBHMY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 41 cases where SBHMY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on October 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SBHMY as a result. In of 42 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

SBHMY moved below its 50-day moving average on October 16, 2025 date and that indicates a change from an upward trend to a downward trend.

The Aroon Indicator for SBHMY entered a downward trend on October 17, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.713) is normal, around the industry mean (24.226). P/E Ratio (32.036) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (2.631) is also within normal values, averaging (2.181). Dividend Yield (0.012) settles around the average of (0.036) among similar stocks. P/S Ratio (4.103) is also within normal values, averaging (349.660).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. SBHMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBHMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.